RxDoctor Payments Data

Kaitlyn Moore, NP

Adult Health · Hahira, GANPI 1811368939

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Amgen at 54.6% of the total. Reporting peaked in 2023 at $5,004 and has fallen 95.9% since, to $203 in 2025. Among adult health clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,769in general payments, 2019–2025

Across 175 payments — averaging $44.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Novartis$525
  • Eisai Inc.$319
  • AstraZeneca$305
  • GSK$281
  • Pfizer$265
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$3,37543%
  • Travel & lodging$7369%
  • Food & beverage$3,56846%
  • Education$901%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,769 in reported general payments places this provider in the 90th percentile of 577 adult health providers in Georgia.

See all adult health providers in Georgia

Medicare billing

Part B allowed, 2024
$22,190
Medicare patients
344
Services billed
416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$9,989
Potassium Chloride47$891
ValacyclovirValacyclovir Hcl11$463
Letrozole17$439
Tamoxifen Citrate13$343
Megestrol Acetate24$336
Warfarin Sodium68$303
Hydroxyurea12$265
Ciprofloxacin Hcl11$128
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)12$84
Gabapentin13$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$265$9,98915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 577 adult health providers in Georgia.

Other adult health in Hahira

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →